Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
Raghu G, Richeldi L, Fernández Pérez ER, De Salvo MC, Silva RS, Song JW, Ogura T, Xu ZJ, Belloli EA, Zhang X, Seid LL, Poole L; ZEPHYRUS-1 Study Investigators. Raghu G, et al. Among authors: poole l. JAMA. 2024 Aug 6;332(5):380-389. doi: 10.1001/jama.2024.8693. JAMA. 2024. PMID: 38762797 Free PMC article. Clinical Trial.
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Sprung CL, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group. Abraham E, et al. Among authors: poole l. JAMA. 2003 Jul 9;290(2):238-47. doi: 10.1001/jama.290.2.238. JAMA. 2003. PMID: 12851279 Clinical Trial.
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. Abraham E, et al. Among authors: poole l. Lancet. 1998 Mar 28;351(9107):929-33. Lancet. 1998. PMID: 9734938 Clinical Trial.
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, Bradley C, Eyassu M, Besarab A, Leong R, Liu CS, Neff TB, Szczech L, Yu KP. Provenzano R, et al. Among authors: poole l. Nephrol Dial Transplant. 2021 Aug 27;36(9):1717-1730. doi: 10.1093/ndt/gfab051. Nephrol Dial Transplant. 2021. PMID: 33629100 Clinical Trial.
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Among authors: poole l. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: poole l. J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22. J Am Soc Nephrol. 2016. PMID: 26494833 Free PMC article. Clinical Trial.
Unlocking Engagement: Enhancing Participation in Research With Vulnerable Populations.
Rojas-Rozo L, Arsenault-Lapierre G, Dumaresq D, Trépanier T, Lea P, Myers Barnett K, O'Connor D, Fernandez Loughlin R, Miskucza K, Wighton MB, Godard-Sebillotte C, Gruneir A, Beuscart JB, Bronskill SE, Sourial N, Smith EE, Bethell J, Vedel I; COVID ROSA Research Team. Rojas-Rozo L, et al. Int J Public Health. 2024 Oct 31;69:1606705. doi: 10.3389/ijph.2024.1606705. eCollection 2024. Int J Public Health. 2024. PMID: 39568528 Free PMC article. No abstract available.
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS. Lu S, et al. Among authors: poole l. Ann Oncol. 2024 Sep 11:S0923-7534(24)03823-7. doi: 10.1016/j.annonc.2024.08.2243. Online ahead of print. Ann Oncol. 2024. PMID: 39289145 Free article.
419 results